Human T-Cell Lymphotropic Virus (HTLV) I/II Antibody Screen
The human T-lymphotropic virus type I (HTLV-1) is a human retrovirus associated with hematological and neurological diseases. HTLV-I infection has been shown to be associated with B- and T-cell chronic lymphatic leukemia (CLL), lymphoma, demyelinating disease, multiple myeloma, some cases of non-Hodgkin’s lymphoma (NHL), polymyositis, arthritis, Kaposi’s sarcoma, uveitis, strongyloidiasis and mycosis fungoides. HTLV-I is endemic in some Caribbean countries, Southern Japan, and possibly in some areas of Africa. In the United States, HTLV-I has been identified in ATL patients, intravenous drug abusers, and in healthy individuals.
HTLV-II is very similar to HTLV-I. It is endemic in several Amerindian tribes, but has not been unequivocally proven to be a pathogen. A high rate of HTLV-II seropositivity has been observed among intravenous drug abusers. HTLV-II infections may present as an atypical T-cell variant of hairy cell leukemia. More recent observations led to the conclusion that HTLV-II may be associated with large granular lymphocyte leukemia (LGL), leukopenic chronic T-cell leukemia, T-prolymphocytic leukemia, mycosis fungoides and chronic neurodegenerative diseases like myelopathy and spastic ataxia. Antibodies to HTLV-II are significantly cross-reactive to HTLV-I antigens.
Transmission of HTLV-I and HTLV-II infections to transfusion recipients by infected cellular blood products is well documented. Other known modes of transmission include breast milk, sexual contact, and sharing of contaminated needles and syringes by intravenous drug abusers. Perinatal transmission is suspected but remains unproven.
- Screening individual human donors, or whole blood and blood components, and other living donors for the presence of anti-HTLV-I/HTLV-II
- As an aid in clinical diagnosis of HTLV-I or HTLV-II infection and related diseases
- Confirmatory testing of Molecular testing (e.g., HTLV I/II by PCR)
HTLV-I, Positive in:
- T-cell leukemia, lymphoma, demyelinating disease
- Adult T-Cell Leukemia (ATL)
- Demyelinating neurologic disorder
- Tropical Spastic Paraparesis/HTLV-I Associated Myelopathy (TSP/HAM)
- B- and T-cell chronic lymphatic leukemia (CLL)
- Multiple myeloma
- Non-Hodgkin’s lymphoma (NHL)
- Polymyositis
- Arthritis
- Kaposi’s sarcoma
- Uveitis
- Strongyloidiasis
- Mycosis fungoides
HTLV-II Positive in:
- Hairy cell leukemia
- Large granular lymphocyte leukemia (LGL)
- Leukopenic chronic T-cell leukemia
- T-prolymphocytic leukemia
- Mycosis fungoides
- Chronic neurodegenerative diseases like myelopathy
- Spastic ataxia
If antibody screening is positive, the donor should be disqualified. For confirmation of Human T-Lymphotropic Virus Types I/II Antibodies, Western Blot can be used.
If the test is used for diagnosis of Human T-Lymphotropic Virus Types I/II, Quantitative Real-Time PCR should be used for confirmation.
Negative (Non-reactive)
Serum (SST), Plasma, (purple top tube/EDTA).
Stability
- Room temperature: 1-3 days
- Refrigerated: 7-14 days
- Curr Opin Virol. 2012 Aug;2(4):474-81. [PMID: 22819021]
- J Infect Dis. 1983; 147(3):406-416. [PMID: 6300254]
- Int J Cancer. 1982; 29:631-635. [PMID: 6980846]
- J Infect Dis. 1983 Mar;147(3):406-16. [PMID: 6300254]
- Hematol Oncol. 1983 Jul-Sep;1(3):193-204. [PMID: 6329935]
- Prog Clin Biol Res. 1985;182:223-43. [PMID: 2994100]
- Cancer Res. 1985 Sep;45(9 Suppl):4637s-4643s. [PMID: 2990699]
- Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):563-72. [PMID: 10591085]
- Science.1987; 236: 1103-6. [PMID: 2883731]